Phase III Study Evaluating Palbociclib (PD-0332991), a C

Project: Research project

Project Details

Description

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope B)
StatusActive
Effective start/end date3/1/155/1/21

Funding

  • NAT'L SURGICAL ADJ BREAST & BOWEL PROJ.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.